GlobeNewswire
-
Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP)
16/11/2026 -
NTG Nordic Transport Group A/S – Capital Markets Day Agenda
16/11/2026 -
Arexera Therapeutics Highlights Potentially Best-in-Class Preclinical Profile and Initiates Clinical Development for ATL-101 in Huntington’s Disease
16/11/2026 -
Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM
16/11/2026 -
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®
16/11/2026 -
ResearchedPeptides.ca Announced as #1 Retatrutide Supplier in Canada by totimes.ca
16/11/2026 -
Mesoblast Showcased at ASX Premier Investor Day Event
16/11/2026 -
Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib
16/11/2026 -
Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026
15/11/2026 -
Lexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026
15/11/2026 -
Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results
15/11/2026 -
NeuroKaire To Showcase Breakthrough Blood Test That Ends the Antidepressant Guessing Game at HLTH 2026 Conference
15/11/2026 -
Keto-Mojo Unveils World’s First Photoacoustic Breathalyzer, Advancing Non-Invasive Ketone Monitoring
14/11/2026 -
Grassroot Soccer Honors U.S. Soccer at 2026 Gala, Raising over $2 million for Adolescent Health Programs
15/11/2026 -
Prolynx Presents Preclinical Data at ObesityWeek® 2026 Supporting the Potential for Quarterly Dosing of Ultra-Long-Acting Anti-Obesity Peptides
14/11/2026 -
Oban BioPharma Announces Presentation of Late-Breaking Abstract at Obesity Week® 2026
14/11/2026 -
Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14/11/2026 -
TRexBio Reports Third Quarter 2026 Financial Results and Recent Business Highlights
13/11/2026 -
Femasys Announces Financial Results for Quarter Ended September 30, 2026 and Provides Corporate Update
13/11/2026
Pages